The FDA has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis in patients aged 12 years and older who are AChR or anti-muscle-specific tyrosine kinase antibody ...

In this final part of a recent interview with Jonathan Strober, MD, UCSF Benioff Children's Hospital and phase 2/3 ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and ...

Johnson & Johnson has submitted its first marketing application for nipocalimab, seeking approval for the FcRn blocker in generalised myasthenia gravis (gMG), where it would compete with rivals in ...

Johnson & Johnson has reported new phase 3 data with its FcRn blocker nipocalimab in generalised myasthenia gravis (gMG), pointing to data that it says differentiates it from other drugs in the class.

Earlier this year, nipocalimab data from Vivacity-MG3 supported the medication's long-term use in generalized myasthenia gravis when it is added to standard-of-care therapies. In particular ...

Johnson & Johnson forecasts peak annual sales of over $5 billion for its FcRN blocker nipocalimab, which the US Food and Drug Administration recently approved and which the company acquired in its ...

In another development, the FDA has approved Johnson & Johnson’s IMAAVY™ (nipocalimab-aahu) for treating generalized myasthenia gravis (gMG) in patients aged 12 and older. This approval is ...

In another development, the FDA has approved Johnson & Johnson’s IMAAVY™ (nipocalimab-aahu) for treating generalized myasthenia gravis (gMG) in patients aged 12 and older. This approval is based on ...